Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity

  • Suah Yang
  • , Man Kyu Shim
  • , Woo Jun Kim
  • , Jiwoong Choi
  • , Gi Hoon Nam
  • , Jeongrae Kim
  • , Jinseong Kim
  • , Yujeong Moon
  • , Han Young Kim
  • , Jooho Park
  • , Yoon Park
  • , In San Kim
  • , Ju Hee Ryu*
  • , Kwangmeyung Kim*
    • *Corresponding author for this work

    Research output: Contribution to journal › Article › peer-review

    125 Citations (Scopus)

    Fingerprint

    Dive into the research topics of 'Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity'. Together they form a unique fingerprint.

    Keyphrases

    Medicine and Dentistry

    Pharmacology, Toxicology and Pharmaceutical Science

    Immunology and Microbiology

    Biochemistry, Genetics and Molecular Biology